Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Corcept Therapeutics (CORT) over the last 12 years, with Sep 2025 value amounting to -$46.4 million.

  • Corcept Therapeutics' Cash from Financing Activities fell 120.05% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.7 million, marking a year-over-year decrease of 741.54%. This contributed to the annual value of -$28.3 million for FY2024, which is 80.94% up from last year.
  • Per Corcept Therapeutics' latest filing, its Cash from Financing Activities stood at -$46.4 million for Q3 2025, which was up 54.91% from -$102.9 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Cash from Financing Activities peaked at $766,000 during Q4 2023, and registered a low of -$207.0 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$4.6 million (2024), whereas its average is -$33.3 million.
  • In the last 5 years, Corcept Therapeutics' Cash from Financing Activities slumped by 31,211.50% in 2021 and then spiked by 1,355.74% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Cash from Financing Activities (Quarterly) stood at -$207.0 million in 2021, then skyrocketed by 99.97% to -$61,000 in 2022, then surged by 1,355.74% to $766,000 in 2023, then tumbled by 695.82% to -$4.6 million in 2024, then plummeted by 120.05% to -$46.4 million in 2025.
  • Its last three reported values are -$46.4 million in Q3 2025, -$102.9 million for Q2 2025, and -$39.8 million during Q1 2025.